Aberdeen Group’s Pliant Therapeutics PLRX Stock Holding History

Aberdeen Group’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-19,724	Closed	-$412K	–	926
2022 Q3	$412K	Buy	+19,724	New	+$377K	﹤0.01%	858

Other funds holding PLRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Aberdeen Group's PLRX Position: Q4 2022 in Review

Aberdeen Group sold out of Pliant Therapeutics (PLRX) in Q4 2022, closing a stake of 19,724 shares — an estimated $412K sold.

Aberdeen Group first reported a position in PLRX in Q3 2022 and held it in 1 quarter. The position peaked at $412K in Q3 2022. 125 funds tracked by Wall St. Rank hold PLRX as of Q4 2022.

Aberdeen Group reported no remaining Pliant Therapeutics position as of Q4 2022 after selling out during the quarter.
Aberdeen Group sold 19,724 Pliant Therapeutics shares in Q4 2022, an estimated $412K.
Aberdeen Group first reported a position in Pliant Therapeutics in Q3 2022 and held it in 1 quarter.
Aberdeen Group's Pliant Therapeutics position peaked at $412K in Q3 2022.
125 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q4 2022.

Based on Aberdeen Group's 13F filing for Q4 2022, filed 10 Feb 2023.